We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
News

MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody

MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
News

MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MRC Technology has announced that it has successfully humanized an anti-CD146 monoclonal antibody.

The project forms part of an on-going collaboration between MRC Technology and the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) to develop the antibody as a cancer therapeutic.

The cell adhesion molecule CD146 plays a critical role in tumour angiogenesis, an essential process for cancer development and metastasis.

Researchers in the lab of Prof Xiyun Yan at IBP CAS developed an anti-CD146 monoclonal antibody that dramatically inhibits tumour angiogenesis, migration and invasion.

Humanization of the antibody is an essential step in the development of anti-CD146 as a therapeutic.

Dave Tapolczay, MRC Technology’s CEO said: “The IBP CAS is one of the world’s leading academic research institutions and we are very pleased with the results of this collaboration. We are hopeful that the positive evaluation results for the humanized antibody will prove to be a significant milestone in cancer therapy and the fight against the disease.”

MRC Technology has humanized over 50 antibodies to date, including two marketed products, Tysabri (natalizumab) and Actemra (tocilizumab).

A further six are in clinical trials (including vedolizumab) and two more in preclinical studies.

Advertisement